glutathione s transferase liver isozyme Glutathione-S-Transferases as Potential Targets for Modulation of Nitric Oxide-Mediated Vasodilation The triple role of glutathione

Eye gaze as a biomarker in the recognition of autism spectrum disorder using virtual reality and machine learning: a proof of concept for diagnosis

Exosomal LncRNA LINC00659 transferred from cancer-associated fibroblasts promotes colorectal cancer cell progression via miR-342-3p/ANXA2 axis

Journal of Chromatographic Science

Farina M, Ribeiro ML, Weissmann C, Estevez A, Billi S, Vercelli C, et al

Tehsil Baddi, Distt

Disclosures: Joanne Hsieh: Gordian Biotechnology: Employee, Vinay Kartha: Nothing to Disclose, Hikaru Miyazaki: Nothing to Disclose, Christopher Carrico: Nothing to Disclose, Linda Chio: Gordian Biotechnology: Employee, Gordian Biotechnology: Stock privately held company, Daniel Fuentes: Nothing to Disclose, Dimitry Popov: Nothing to Disclose, Ian Driver: Nothing to Disclose, Chris Towne: Nothing to Disclose, Francisco LePort: Nothing to Disclose, Martin Borch Jensen: Nothing to Disclose 2067 PHARMACOKINETICS, SAFETY AND EFFICACY OF THE NOVEL NON-BILE ACID FXR AGONIST FXR314 IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: RESULTS FROM A PHASE 2 STUDY Eric Lawitz 1 Kathryn Jean Lucas 2 Kris Kowdley 3 Naim Alkhouri 4 Stephen Harrison 5 Fabrice Piu 6 , 1 Texas Liver Institute, 2 Diabetes & Endocrinology Consultants, PC, 3 Liver Institute Northwest, 4 Arizona Liver Health, 5 University of Oxford, 6 Organovo, Inc Background Farnesoid X receptor (FXR) agonism has demonstrated clinical utility for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) but clinical development has been hampered by limited efficacy and adverse events (pruritus, dyslipidemia)